Presentation is loading. Please wait.

Presentation is loading. Please wait.

Schema of the exploratory analyses (RAS wild-type population)

Published bySerafina Innocenti Modified over 5 years ago

Similar presentations

Presentation on theme: "Schema of the exploratory analyses (RAS wild-type population)"— Presentation transcript:

1 Schema of the exploratory analyses (RAS wild-type population)
Schema of the exploratory analyses (RAS wild-type population). EGFRi, epidermal growth factor receptor inhibitor; FOLFIRI, folinic acid, 5-fluorouracil and irinotecan; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; OS, overall survival; PEAK,  Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with KRAS WT tumours; PRIME, Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy; R, randomisation; VEGFi, vascular endothelial growth factor inhibitor. Schema of the exploratory analyses (RAS wild-type population). EGFRi, epidermal growth factor receptor inhibitor; FOLFIRI, folinic acid, 5-fluorouracil and irinotecan; FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; OS, overall survival; PEAK,  Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with KRAS WT tumours; PRIME, Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy; R, randomisation; VEGFi, vascular endothelial growth factor inhibitor. Marc Peeters et al. ESMO Open 2018;3:e000297 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Schema of the exploratory analyses (RAS wild-type population)"

Similar presentations

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.
Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology www.bowelcancerwest.org.uk.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology
Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts 4032-4035 Jeffrey Meyerhardt,

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,
Www.OncologyEducation.ca Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.

Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Power to the Patient With Cancer: Aligning Communication Between Patients and Clinicians This program is supported by an educational grant from Genentech.

Power to the Patient With Cancer: Aligning Communication Between Patients and Clinicians This program is supported by an educational grant from Genentech.
CCO Independent Conference Coverage

CCO Independent Conference Coverage
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) 

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) 
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.

Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.
CLINICAL AND BUDGET IMPACT OF USING A MOLECULAR TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES Cheng I1, Hertz.

CLINICAL AND BUDGET IMPACT OF USING A MOLECULAR TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES Cheng I1, Hertz.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Axel Grothey Professor of Oncology Mayo Clinic Rochester

Axel Grothey Professor of Oncology Mayo Clinic Rochester
Reviewer: Dr Scott Berry Date posted: June 21, 2007

Reviewer: Dr Scott Berry Date posted: June 21, 2007
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Similar presentations

Ads by Google